BELLUS Health Inc. – “We Have a Plan”

NEW YORK, NY / ACCESSWIRE / March 17, 2015 / BELLUS Health Inc. (TSX: BLU) today published a new blog post on The Chairman’s Blog, written by the Company’s President and Chief Executive Officer, Roberto Bellini. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. 

In his inaugural blog post, Mr. Bellini reflects on his start as CEO of BELLUS Health in 2010 and discusses the Company’s plans for its key programs, KIACTA for AA amyloidosis, KIACTA for Sarcoidosis and Shigamab for sHUS, moving forward. He goes on to share why he is passionate about the biotechnology industry and highlights why he wants to increase communication with the BELLUS’s stakeholders. Read the full blog post from Mr. Bellini on TheChairmansBlog.com (http://www.thechairmansblog.com/bellus-health-inc/roberto-bellini/we-have-a-plan/). 

About BELLUS Health Inc. 

BELLUS Health is a drug development company focused on rare diseases. It has a portfolio of rare disease projects including KIACTA(TM) in Phase III for AA amyloidosis, KIACTA(TM) for sarcoidosis, clinical stage ShigamabTM for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA(TM) is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. KIACTA(TM) is partnered with global private equity firm Auven Therapeutics.

About TheChairmansBlog.com 

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.

SOURCE: The Chairman’s Blog

ReleaseID: 426956